What are amantadine and memantine, and what are the differences between them?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Amantadine and Memantine: Two Distinct NMDA Receptor Antagonists

Amantadine and memantine are both adamantane derivatives that block NMDA receptors, but they have fundamentally different clinical applications: memantine is FDA-approved for moderate to severe Alzheimer's disease dementia, while amantadine is primarily used for Parkinson's disease and has antiviral properties. 1

Mechanism of Action

Both drugs work as uncompetitive NMDA receptor antagonists (also called open-channel blockers), but with critical differences:

Memantine

  • Low to moderate affinity NMDA receptor antagonist that binds preferentially to NMDA receptor-operated cation channels 1
  • Blocks pathological, chronic low-level activation of NMDA receptors while preserving normal synaptic function due to its fast blocking/unblocking kinetics and strong voltage-dependency 2
  • Shows partial trapping - releases from one-sixth of blocked channels rather than being trapped in all of them, allowing some channels to release the blocker between synaptic responses 3
  • Does not significantly interact with the CYP450 enzyme system 1

Amantadine

  • Also an NMDA receptor antagonist but with different pharmacodynamic properties that affect striatal dopaminergic transmission differently than memantine 4
  • Has additional effects on dopamine receptors and dopamine transporter function 4
  • Shows complete trapping in NMDA channels, unlike memantine's partial trapping 3
  • Has antiviral properties and affects multiple neurotransmitter systems 5

Clinical Applications

Memantine

  • FDA-approved for moderate to severe Alzheimer's disease 1
  • Improves cognition and global assessment in moderate to severe dementia, though effect sizes may not reach clinically significant thresholds 6
  • Can be used as monotherapy or combined with cholinesterase inhibitors like donepezil 6
  • Shows benefit in quality of life outcomes for patients with moderate to severe Alzheimer's disease 6
  • May benefit REM sleep behavior disorder in Parkinson's disease 7

Amantadine

  • Primarily used for Parkinson's disease - not for cognitive enhancement 8
  • Used as an antiviral agent 5
  • Treats fatigue in Multiple Sclerosis 5
  • Does not have significant pro-cognitive effects unlike memantine 8

Key Pharmacological Differences

The critical distinction is that while both are NMDA antagonists, memantine has selective benefits for dementia while amantadine carries notable cognitive risks:

  • Memantine improves attention and behavioral symptoms in PD dementia 7
  • Extended-release amantadine increases hallucinations and cognitive impairment 7
  • Memantine exhibits PCP-like discriminative stimulus effects in animal models, while amantadine does not 9
  • Memantine can serve as a reinforcer (suggesting abuse potential at supratherapeutic doses), while amantadine shows minimal reinforcing properties 9

Dosing and Safety

Memantine 1

  • Highly absorbed orally with peak concentrations at 3-7 hours
  • Terminal elimination half-life: 60-80 hours
  • Excreted predominantly unchanged in urine (48%)
  • Dose reduction required in severe renal impairment (not mild/moderate)
  • Use with caution in severe hepatic impairment
  • Common side effects: dizziness, headache, confusion, constipation 1

Amantadine

  • Different dopaminergic effects that distinguish it from memantine 4
  • Risk of hallucinations and cognitive worsening, particularly with extended-release formulations 7

Clinical Decision-Making

When choosing between these agents, the indication drives the choice:

  • For Alzheimer's disease dementia (moderate to severe): Use memantine 6, 10
  • For Parkinson's disease motor symptoms: Use amantadine (not memantine for this indication)
  • For cognitive symptoms in Parkinson's disease: Consider memantine cautiously; avoid amantadine due to cognitive risks 7

Critical caveat: The evidence shows that benefits of memantine in dementia are modest - only about 9% of patients show global response in excess of placebo 6. Base the decision to use memantine on tolerability, adverse effect profile, ease of use, and cost since head-to-head comparisons are lacking 10. If a beneficial effect occurs, it should be observed within 3 months 10.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.